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ABSTRACT  
Background: 
Post-tuberculosis lung damage (PTLD) is a recognised consequence of pulmonary TB (pTB). However, 
little is known about its prevalence, patterns, and associated outcomes, especially in sub-Saharan 
Africa and HIV-positive adults.  
Methods: 
Adult (≥15 years) survivors of a first episode of pTB in Blantyre, Malawi completed the St George’s 
Respiratory Questionnaire, six-minute walk test, spirometry, and high-resolution computed 
tomography (HRCT) chest imaging at TB treatment completion. Symptom, spirometry, health 
seeking, TB-retreatment and mortality data were collected prospectively to one-year. Risk factors for 
persistent symptoms, pulmonary function decline, and respiratory-related health-seeking were 
identified through multivariable regression modelling. 
Results:  
Between February 2016 and April 2017, 405 participants were recruited. Median age was 35 years 
(IQR:28-41), 77.3% (313/405) had had microbiologically proven pTB, and 60.3% (244/403) were HIV-
positive. Upon pTB treatment completion, 60.7% (246/405, 95% CI: 55.8 – 65.5%) reported 
respiratory symptoms, 34.2% (125/365, 95% CI: 29.4 – 39.4%) had abnormal spirometry, 44.2% 
(170/385, 95% CI: 39.1 – 49.3%) had bronchiectasis ≥1 lobe, and 9.4% (36/385, 95% CI: 6.6 – 12.7%) 
had ≥1 destroyed lobe on HRCT imaging. At one-year, 30.7% (113/368, 95% CI: 26.0 – 35.7%) reported 
respiratory symptoms, 19.3% (59/305, 95% CI: 15.1 – 24.2%) and 14.1% (43/305, 95% CI: 10.4 – 
18.5%) of patients had experienced declines in FEV1 or FVC of ≥100ml, 16.3% (62/380, 95% CI: 12.7 – 
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20.4%) had reported ≥1 acute respiratory event, and 12% (45/368, 95% CI: 9.1 – 16.0%) had 
symptoms affecting their ability to work.  
Conclusions: 
PTLD is a common and under-recognised consequence of pTB that is disabling for patients and 
associated with adverse outcomes beyond pTB treatment completion.  Increased efforts to prevent 
PTLD and guidelines for management of established disease are urgently needed. Low-cost clinical 
interventions to improve patient outcomes must be evaluated. 
 
Word count: 277 words  
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KEY MESSAGES 
What is the key question? 
What is the burden of post-tuberculosis lung damage (PTLD) amongst adults successfully completing 
pulmonary tuberculosis (pTB) treatment in urban Malawi, and what are the associated patient 
outcomes? 
What is the bottom line? 
pTB-survivors have a high burden of post-TB lung damage, which is largely undiagnosed within 
existing TB management pathways, and is associated with adverse patient outcomes including 
accelerated lung function decline, ongoing respiratory-related health seeking, persistent chest 
symptoms, and difficulty working in the year after treatment completion. 
Why read on? 
This work provides a detailed description of post-TB lung damage and associated outcomes amongst 
both HIV-positive and negative adults successfully completing pTB treatment in Malawi, and suggests 
research priorities for the prevention and management of disease.  
 
  
6 
 
INTRODUCTION  
An estimated ten million incident cases of tuberculosis disease occurred globally in 2017, one quarter 
of which were in sub-Saharan Africa (sSA) where 30% (24-35%) of patients are HIV co-infected.(1) TB 
mortality is falling, and 82% of people treated for a first episode of TB now survive with treatment 
success (cure or completion).(1) 
Post-TB lung damage (PTLD) is a recognised consequence of pulmonary TB (pTB) disease: adult pTB-
survivors have two-to-four-fold higher odds of persistently abnormal spirometry (airway obstruction 
and restriction) compared to those without previous TB disease,(2-4) with parenchymal and airway 
abnormalities seen on imaging,(5, 6) and associated respiratory symptoms and reduced quality of 
life.(7-10) However, there are few estimates of the burden of disease at pTB treatment completion, 
and few prospective data on the medium or long-term consequences of PTLD or risk factors for 
adverse patient outcomes. Data are particularly scarce for adults in low-income settings with HIV co-
infection.(5) There remain no standardised guidelines for the diagnosis and management of 
PTLD.(11) 
Cohort studies from resource-rich settings suggest a correlation between the severity of chronic lung 
diseases and accelerated spirometry decline, hospital admissions, and increased mortality.(12-14) 
We hypothesise that adults with PTLD in low-income settings could experience similar – or more 
severe – adverse outcomes.  
In this prospective cohort study in Malawi – one of the poorest countries in the world – we 
investigated the prevalence and pattern of residual lung damage at TB treatment completion using 
gold-standard respiratory investigations including high-resolution computed tomography (HRCT) 
imaging and spirometry, with findings disaggregated by HIV-status. The evolution of pathology in the 
year following treatment completion is described and predictors of adverse outcomes identified. 
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METHODS  
HIV-positive and -negative adults expected to complete treatment for pulmonary TB (pTB) at nine 
health centres in urban Blantyre, Malawi between February 2016 and April 2017 were prospectively 
identified using the Malawi National Treatment Programme (NTP) registry. These individuals were 
screened by the study team at their monthly medication collection visits, with multiple opportunities 
available to identify each individual, and formal recruitment was completed at the end of treatment. 
Inclusion criteria were: age ≥15yrs; residence in urban Blantyre; treatment for a first episode of pTB 
with cure or completion as defined by the NTP. Those with persistent symptoms at treatment 
completion underwent additional screening with sputum smear & TB culture and were excluded if 
either were positive. We excluded patients treated as multi-drug resistant disease (MDR-TB 
prevalence amongst new TB cases in Malawi: 0.75%).(15)  
Study visits were conducted at the central hospital within one-month of pTB treatment completion, 
and at six-months (home visit) and 12-months (hospital visit) after treatment end. Participants 
completed: questionnaires (demographics, respiratory exposures, socio-economic data); the St 
George’s Respiratory Questionnaire (SGRQ); six-minute walk test; pre- and post- bronchodilator 
spirometry; blood tests (FBC, CD4 cell count, Aspergillus IgG). Imaging included chest radiography 
(CXR) at baseline and 12-months, and non-contrast high-resolution computed tomography (HRCT) 
chest imaging at baseline. Questionnaires and spirometry were repeated at all visits, and data on 
health seeking, TB retreatment and all-cause mortality were determined from participant-held 
health-records. Details of existing cardio-respiratory diagnoses were obtained from health-records, 
and TB microbiology at pTB diagnosis from NTP registers.  
Questionnaires were conducted in the local language, Chichewa. HIV testing was offered to 
participants of unknown serostatus, and those who had tested over 1-month before recruitment 
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(Serial testing with Determine 1/2™; Alere, USA / Uni-Gold™; Recombigen® HIV, Trinity Biotech, 
Ireland). Plasma anti-aspergillus fumigatus IgG was measured by ELISA (Bordier Affinity Products), 
using a cut-off index >1.0 for a positive result. Six-minute walk tests and spirometry (EasyOne, ndd 
Medical Technologies) were conducted to American Thoracic Society (ATS) standards.(16, 17) HRCT 
imaging was performed using a pre-specified protocol (Appendix 1). Participants underwent 
protocol-driven clinical review for investigation results requiring urgent intervention but attended 
routine clinical services for all other illness episodes.  
Quality control & data interpretation 
Details of spirometry and imaging acquisition, quality control and interpretation are given in the 
online data supplement. Briefly, only spirometry data meeting BOLD-standards were included in 
analyses (Appendix 2). Data were standardised using the Global Lung Initiative 2012 (GLI-2012) 
African reference ranges.(18) Patterns of abnormality (obstruction: FEV1/FVC ratio < lower limit of 
normal (LLN); low FVC: FEV1/FVC ratio ≥LLN & FVC<LLN; normal: FEV1/FVC ratio ≥LLN & FVC≥LLN) and 
reversibility (>200ml and >12% increase in absolute FEV1 or FVC following bronchodilator) were 
described.(19) HRCT images were independently read by two consultant radiologists with consensus 
review of discrepant findings (Appendix 3). The extent and severity of Fleischner-defined airway, 
parenchymal and pleural pathologies were recorded.(20) Lobes where ≥90% of parenchyma was 
replaced by banding, atelectasis, or cavities/cystic airspaces were classified as ‘destroyed’. 
Agreement between readers was measured using intraclass correlation coefficients and Kappa 
scores. 
Statistical methods 
A sample size of 400 allowed us to estimate the prevalence of PTLD with a margin of error less than 
5% with 95% confidence (Appendix 4). We described the burden of respiratory pathology using 
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clinical, spirometry and imaging parameters, stratified by HIV-status. Chi-square, Student’s t-test, 
Fisher’s exact or Wilcoxon rank sum tests were used to compare between groups. We compared the 
age-stratified prevalence of abnormal spirometry to recent community-based data from urban 
Blantyre in sensitivity analyses.(21) Exploratory analyses were conducted to determine the 
relationship between symptoms, and spirometry and imaging parameters.  
We determined the proportion of participants experiencing pre-specified adverse outcomes over 
one-year including: accelerated decline in FEV1 and FVC (loss ≥100ml); chronic respiratory symptoms 
at one-year (cough, breathlessness, sputum, or wheeze ≥few days/month); TB-retreatment; and all-
cause mortality. We recorded the number of acute respiratory events, defined as ‘an unscheduled 
visit to health care provider, either outpatient or inpatient, due to a respiratory complaint (cough, 
breathlessness, sputum, wheeze, chest pain)’.  
We used linear mixed-effects and logistic models to estimate predictors of FEV1 and FVC over time 
and the prevalence of chronic respiratory symptoms and respiratory events by one-year. Models 
were built using a pre-specified set of covariates. Fixed effects and variance components were 
reported for linear mixed effects models, and coefficient estimates or odds ratios with 95% 
confidence intervals (CIs) otherwise. Separate outcome models were constructed using FEV1 and FVC 
as predictors, due to co-linearity. Complete case analyses were performed in Stata 15 (StataCorp).  
Approvals & permissions 
All participants provided written informed consent. Ethical approval was obtained from the Liverpool 
School of Tropical Medicine (LSTM) (15.040RS) and Malawi College of Medicine Research Ethics 
(P.10/15/1813) Committees.  
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RESULTS  
450 pTB-survivors were screened for eligibility, of whom 405 met inclusion criteria at TB treatment 
completion (Figure 1). 37/405 (9.1%) participants did not complete the final study visit: 22 relocated, 
11 died, three withdrew and one was lost to follow-up. Participants not completing study procedures 
at one-year had similar characteristics (age, sex, HIV status, TB microbiology, SES, ever 
smoking/cannabis use) to those completing the study, but a higher prevalence of respiratory 
symptoms at baseline (75.7% [28/37] vs. 59.2% [218/368], p=0.051). 
Participant characteristics 
Median age was 35 years (interquartile range [IQR]: 28-41), 67.9% (275/405) were male, and 77.3% 
(313/405) had microbiologically proven pTB disease (Table 1). Amongst the 60.5% (244/403) who 
were HIV-positive, the majority were receiving antiretroviral therapy (91.8% [224/244]) and 
cotrimoxazole (90.2% [211/234]) with a median CD4 count of 229 cells/L (IQR: 127–397) and median 
ART duration of 6.6 months (IQR: 5.5 – 25.6) by TB treatment completion. The median self-reported 
duration of illness prior to TB treatment initiation was 8.7 weeks (IQR: 4.0 – 13.0). 
Socioeconomic deprivation was common: 38.0% (154/405) were educated to primary school level 
only, 31.6% (128/405) reported intermittent food insecurity, and 73.5% (298/405) had incurred 
dissaving (borrowing money, selling assets, or using savings) to cover health-care costs during TB 
illness or treatment.  
Overall, 29.6% (285/405) of participants had ever-smoked, with a median of 2.7 pack-year (IQR: 0.7-
6.0) exposure, and 13.3% (54/362) had ever-used cannabis. Use of biomass fuels for cooking/heating 
was reported by 94.8% (384/405). Only 2.2% (9/405) of the cohort had an established diagnosis of 
chronic lung disease (bronchitis n=4, asthma n=5) by treatment completion. 
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Table 1: Participant characteristics, stratified by HIV status† 
Characteristic Total  (n=405) 
HIV-negative  
(n=159) 
HIV-positive 
(n=244) 
p-value 
Age (yrs) (median, IQR) 35 (28 – 41) 30 (24 – 37) 37 (32 – 42) <0.001* 
Male sex 275 (67.9%) 115 (72.3%) 158 (64.8%) 0.112 
Urban SES quintile (n=372) † 
- Poorest  
- 2nd poorest 
- Middle 
- 2nd most wealthy 
- Most wealthy 
 
22 (5.9%) 
85 (22.8%) 
95 (25.5%) 
114 (30.7%) 
56 (15.1%) 
 
10 (7.1%) 
28 (19.9%) 
36 (25.5%) 
48 (34.0%) 
19 (13.5%) 
 
12 (5.2%) 
57 (24.9%) 
58 (25.3%) 
66 (28.8%) 
36 (15.7%) 
 
0.638 
Maximum education level ≤ primary school 154 (38.0%) 49 (30.8%) 104 (42.6%) 0.017* 
Intermittent difficulty procuring food for 
household 
128 (31.6%) 47 (29.6%) 81 (33.2%) 0.443 
Household dissaving incurred in past one-yr 
to cover illness costs ‡ 
298 (73.6%) 109 (68.6%) 189 (77.5%) 0.047* 
Monthly individual income ($US) § 41.32 (11.02 – 96.42) 37.47 (5.51 – 82.64) 46.83 (16.53 – 99.17) 0.206 
Baseline TB microbiology 
- Smear positive 
- Xpert positive, Rifampicin sensitive 
- Radiological diagnosis 
- Clinical diagnosis 
 
213 (52.6%) 
100 (24.7%) 
54 (13.3%) 
38 (9.4%) 
 
118 (74.2%) 
21 (13.2%) 
10 (6.3%) 
10 (6.3%) 
 
95 (38.9%) 
78 (32.0%) 
43 (17.6%) 
28 (11.5%) 
 
<0.001* 
Self-reported illness duration prior to TB 
treatment (weeks) 
8.7 (4.3 – 13.0) 8.7 (4.3 – 13.0) 8.7 (4.3 – 17.4) 0.759 
ART use, if HIV-positive (n=244) ǁ   224 (91.8%)  
Duration on ART, if HIV-positive (months) 
(n=222) 
  6.6 (5.5 – 25.6)  
Prophylactic cotrimoxazole use, if HIV-
positive (n=234) 
  211 (90.2%)  
CD4, if HIV-positive (cells/µL) (n=242)   229 (127 – 397)  
Ever smoker, cigarettes 120 (29.6%) 56 (35.2%) 62 (25.4%) 0.034* 
Pack years, amongst smokers (n=120) 2.7 (0.7 – 6.0) 2.1 (0.7 – 5.6) 2.9 (0.7 – 7.0) 0.465 
Ever smoker, cannabis (n=362)† 54 (14.9%) 35 (25.4%) 19 (8.6%) <0.001* 
Charcoal / wood as main fuel  384 (94.8%) 153 (96.2%) 229 (93.9%) 0.295 
* Statistically significant difference between HIV-positive and negative groups, at p<0.05 level. 
† Missing data: HIV status for n=2 (declined to test, included in ‘total’ column only), Socio-Economic Status (SES) for n=33 (unable to 
visit household to determine building materials), Cannabis use for n=43 (unbiased data collection error). 
‡ Borrowing money, using savings, selling assets to cover costs due to illness, in past 1yr (during TB illness and treatment). 
§ Income data collected in Malawi Kwacha, but standardised using exchange rate at study midpoint ($1 USD: 726 MK, March 2017). 
ǁ 97% (218/224) receiving Regimen 5a (tenofovir, lamivudine, efavirenz) at TB treatment completion. 
 
Residual lung pathology at TB treatment completion 
A majority of participants, 60.7% (246/405, 95% CI: 55.8 – 65.5%), reported one or more respiratory 
symptom at TB treatment completion (Table 2). Median SGRQ total score was 8.8 (IQR: 1.3–23.4) and 
40.0% (162/405, 95% CI: 35.2 – 45.0%) reported chest symptoms interfering with work. Median 
oxygen saturation was 98% (IQR: 97-99%). Hypoxaemia (<92%) was observed in 1.5% (6/405, 95% CI: 
0.5 – 3.2%) at rest, and 3.8% (15/395, 95% CI: 2.1 – 6.2%) after the 6-minute walk test. 17.5% (71/405, 
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95% CI: 14.0 – 21.6%) of participants were underweight (BMI <18.5 kg/m2). Median haemoglobin was 
13.7 g/dL (IQR: 12.3 – 15.1). Few participants (0.7% [3/405, 95% CI: 0.1 – 2.1%]) had positive 
A.fumigatus IgG serology (ELISA index > 1.0).  
BOLD standard post-bronchodilator spirometry data were available for 90.1% (365/405) of 
participants. Mean z-scores for the FEV1, FVC, and FEV1/FVC ratio were negative (-1.06 [standard 
deviation(SD): 1.26], -0.91 [1.23], -0.38 [1.26], respectively). When classified into patterns, 20.0% 
(73/365, 95% CI: 16.0 – 24.4%) had a low FVC pattern and 14.2% (52/365, 95% CI: 10.8 – 18.3%) had 
airway obstruction. Amongst those with airway obstruction 9.6% (5/52, 95% CI: 3.2 – 21.0%) had 
reversibility. When the age-stratified prevalence of moderate-severe obstruction and low FVC 
patterns were compared with recent community-based data from urban Blantyre,(21) the prevalence 
of both obstructive and low FVC patterns were higher in this post-TB cohort across age-strata 
(Appendix 5).  
The prevalence of cough and exertional breathlessness were higher amongst HIV-negative compared 
to positive participants (45.9% [73/159] vs. 29.5% [72/244], p=0.002 and 50.0% [79/158] vs. 39.5% 
[96/243], p=0.038 respectively). Mean FEV1 and FVC z-scores were also significantly lower amongst 
HIV-negative participants (-1.27 [SD:1.33] vs. -0.94 [1.19], p=0.015 and -1.08 [1.29] vs. -0.80 [1.18], 
p=0.037) (Appendix 6). 
In total 385 HRCT scans were completed, with 77.7% (299/385) within two-months of TB treatment 
completion. Inter-reader agreement for the extent of Fleischner-defined parenchymal (ICC: 0.43 –
0.81) and airway abnormalities (Kappa: 0.42 – 0.72) were good to excellent (Appendix 3).(20) 
Moderate to severe bronchiectasis was seen in ≥1 lobe in 44.2% (170/385, 95% CI: 39.1 – 49.3%) of 
participants: 7.5% (29/385, 95% CI: 5.1 – 10.6%) had involvement of ≥3 lobes, and 12.7% (49/385, 
95% CI: 9.6 – 16.5%) had cystic bronchiectasis. The median amount of abnormal parenchyma was 
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22.9% (IQR: 9.2 – 39.2%). Atelectasis and banding, and mosaicism were the most common patterns 
seen, and 9.4% (36/385, 95% CI: 6.6 – 12.7%) of participants had ≥1 destroyed lobe (Figure 2). On 
average, the majority of airways and parenchymal pathologies were more extensive in HIV-negative 
compared to HIV-positive participants (Figure 3, Appendix 7). However residual consolidation, 
ground glass opacification, and nodules were widespread (prevalence 69.4% [267/385, 95% CI: 64.5 
– 73.9%], 36.6% [141/385, 95% CI: 31.8 – 41.7%], and 59.2% [228/385, 95% CI: 54.1 – 64.2%], 
respectively) with no significant difference by HIV-status.  
Participants with weekly or monthly respiratory symptoms at TB treatment completion had lower 
FEV1 z-scores (-1.23 [IQR:1.28] vs. -0.79 [IQR:1.19], p<0.001), lower FVC z-scores (-1.05 [IQR:1.25] vs. 
-0.68 [IQR:1.17], p=0.013), more abnormal lung parenchyma (27.3% [95% CI:10.0-42.9%] vs. 18.3% 
[95% CI: 7.1-34.6%], p=0.002), and a higher proportion had ≥1 destroyed lung lobe on HRCT imaging 
(29/234 [12.4%, 95% CI:8.5-17.3%] vs 7/151[4.6%, 95% CI: 1.9-9.3%], p=0.011) compared to those 
without regular symptoms. Those with regular cough had higher bronchiectasis severity scores than 
those without cough (3.0/18 [IQR: 1.0 – 5.5] vs. 2.0/18 [0.5 – 4.5], p=0.014) (Appendix 8).  
Table 2: Clinical and respiratory parameters measured at TB treatment completion, 6-month and 12-month study visits 
Parameter TB treatment 
completion 
(n=405) 
6-month visit 
(n=376) 
12-month visit 
(n=368) 
p-value: 
Baseline vs. 
12-months § 
Self-reported symptom prevalence (%, 95% CI) † 
Breathlessness 
- Never/only with chest infections 
- Few days per month 
- ≥Several days per week 
 
227 (56.0%, 51.1-60.9%) 
161 (39.8%, 35.0-44.7%) 
17 (4.2%, 2.5-6.6%) 
 
283 (75.3%, 70.6-79.5%) 
79 (21.0%, 17.0-25.5%) 
14 (3.7%, 2.1-6.2%)  
 
282 (76.6%, 72.0-80.9%) 
76 (20.7%, 16.6-25.2%) 
10 (2.7%, 1.3-4.9%) 
 
<0.001* 
Cough 
- Never/only with chest infections 
- Few days per month 
- ≥Several days per week 
 
259 (64.0%, 59.1-68.6%) 
135 (33.3%, 28.8-38.2%) 
11 (2.7%, 1.4-4.8%) 
 
284 (75.5%, 70.9-79.8%) 
76 (20.2%, 16.3-24.6%) 
16 (4.3%, 2.5-6.8%) 
 
307 (83.4%, 79.2-87.1%) 
54 (14.7%, 11.2-18.7%) 
7 (1.9%, 0.8-3.9%) 
 
<0.001* 
Sputum production 
- Never/only with chest infections 
- Few days per month 
- ≥Several days per week 
 
300 (74.1%, 69.5-78.3%) 
97 (23.9%, 19.9-28.4%) 
8 (2.0%, 0.9-3.9%) 
 
300 (79.8%, 75.4-83.7%) 
70 (18.6%, 14.8-22.9%) 
6 (1.6%, 0.6-3.4%) 
 
318 (86.4%, 82.5 -89.7) 
47 (12.8%, 9.5-16.6%) 
3 (0.8%, 0.2-2.4%) 
 
<0.001* 
Wheeze 
- Never/only with chest infections 
- Few days per month 
- ≥Several days per week 
 
372 (91.8%, 88.7-94.3%) 
29 (7.2%, 4.8-10.1%) 
4 (1.0%, 0.3-2.5%) 
 
346 (92.0%, 88.8-94.6%) 
28 (7.5%, 5.0-10.6%) 
2 (0.5%, 0.1-1.9%) 
 
352 (95.7%, 93.0-97.5%) 
16 (4.3%, 2.5-7.0%) 
0 
 
0.091 
Any respiratory symptom, ≥monthly 246 (60.7%, 55.8-65.5%) 138 (36.7%, 31.8-41.8%) 113 (30.7%, 26.0-35.7%) <0.001* 
Self-reported symptom impact (%, 95% CI) 
Impact of chest on activities 
- Does not stop any activities 
- Prevents 1-2 activities 
- Prevents most / all activities 
 
200 (49.4%, 44.4-54.4%) 
165 (40.7%, 35.9-45.7%) 
40 (9.9%, 7.2-13.2%) 
 
290 (77.1%, 72.5-81.3%) 
69 (18.4%, 14.6-22.6%) 
17 (4.5%, 2.7-7.1%) 
 
295 (80.2%, 75.7-84.1%) 
57 (15.5%, 11.9-19.6%) 
16 (4.3%, 2.5-7.0%) 
 
<0.001* 
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Impact of chest on work 
- Does not affect work 
- Interferes with / made me change work 
- Made me stop work 
 
243 (60.0%, 55.0-64.8%) 
148 (36.5%, 31.8-41.4%) 
14 (3.5%, 1.9-5.7%) 
 
309 (82.2%, 77.9-85.9%) 
57 (15.2%, 11.7-19.2%) 
10 (2.7%. 1.3-4.8%) 
 
323 (87.8%, 84.0-90.9%) 
38 (10.3%, 7.4-13.9%) 
7 (1.9%, 0.8-3.9%) 
 
<0.001* 
Breathless at rest / during personal care  2 (0.5%, 0.1-1.8%) 2 (0.5%, 0.1-1.9%) 2 (0.5%, 0.1-1.9%) 1.000 
Walks slower than peers / stops for rest at 
own pace 
108 (26.8%, 22.5-31.4%) 57 (15.2%, 11.7-19.2%) 64 (17.4%, 13.7-21.7%) 0.002* 
Breathless on hills 176 (43.7%, 38.8-48.7%) 82 (21.8%, 17.7-26.3%) 83 (22.6%, 18.4 – 27.2%) <0.001* 
Quality of life     
Self-reported general health (%, 95% CI) 
- Poor/fair 
- Good/excellent 
 
115 (28.4%, 24.1-33.1%) 
290 (71.6%, 66.9-75.9%) 
 
54 (14.4%, 11.0-18.3%) 
322 (85.6%, 81.7-89.0%) 
 
22 (6.0%, 3.8-8.9%) 
346 (94.0%, 91.1-96.2%) 
 
<0.001* 
SGRQ Total score (median, IQR) 8.8 (1.3 – 23.4) 0.4 (0 – 10.6) 0.4 (0 – 6.9) <0.001* 
SGRQ Symptom score (median, IQR) 10.3 (2.7 – 23.1) 2.7 (0 – 13.7) 2.7 (0 – 13.7) <0.001* 
SGRQ Activity score (median, IQR) 11.2 (0 – 35.5) 0 (0 – 11.9) 0 (0 – 6.2) <0.001* 
SGRQ Impact score (median, IQR) 5.6 (0 – 15.5) 0 (0 – 5.7) 0 (0 – 3.7) <0.001* 
Clinical observations     
BMI (kg/m2) (median, IQR) 20.5 (19.0 – 22.3) 21.0 (19.4 – 22.7) 21.1 (19.5 – 23.2) <0.001* 
Oxygen saturations (%) (median, IQR) 98 (97 – 99) 98 (97 – 99) 98 (97 – 98) <0.001* 
Hypoxaemia (sats <92%) (%, 95% CI) 6 (1.5%, 0.5-3.2%) 6 (1.6%, 0.6-3.4%) 4 (1.1%, 0.3-2.8%) 0.706 
Respiratory rate (breaths/minute) (median, 
IQR) 
18 (17 – 20) 19 (18 – 21) 20 (19 – 22) <0.001* 
Heart rate (beats/minute) (median, IQR) 78 (68 – 89) 77 (68 – 86) 77 (67 – 86) 0.019* 
Pedal oedema (%, 95% CI) 7 (1.7%, 0.7-3.5%) 3 (0.8%, 0.2-2.3%) 3 (0.8%, 0.2-2.4%) 0.317 
Palatal Kaposi Sarcoma (n=368) (%, 95% CI) 8 (2.2%, 0.9-4.2%) 10 (2.7%, 1.3-4.8%) 1 (0.3%, 0.0-1.5%) 0.008* 
Blood tests     
Haemoglobin (g/dL) (median, IQR) 13.7 (12.3 – 15.1)    
Positive aspergillus IgG ELISA (%, 95% CI) 3 (0.7%, 0.2-2.1%)  2 (0.5%, 0.1-1.9%) 0.564 
6-minute walk test (n=395 / 355)     
Distance (m) (mean, sd) 568m (79.7m)  611.2m (71.0m) <0.001* 
Spirometry (n=365 / 341 / 336) ‡  
FEV1 z-score (mean, sd)  -1.06 (1.26) -0.90 (1.25) -0.88 (1.19) <0.001* 
FVC z-score (mean, sd) -0.91 (1.23) -0.66 (1.19) -0.61 (1.09) <0.001* 
FEV1/FVC ratio z-score (mean, sd) -0.38 (1.26) -0.51 (1.28) -0.54 (1.29) <0.001* 
Pattern of spirometry (%, 95% CI) 
- Obstruction (FEV1/FVC ratio <LLN) 
- Low FVC (FEV1/FVC ratio ≥LLN & 
FVC<LLN) 
- Normal (FEV1/FVC ratio ≥LLN & 
FVC≥LLN) 
 
52 (14.2%, 10.8-18.3%) 
73 (20.0%. 16.0-24.5%) 
 
240 (65.8%, 60.6-70.6%) 
 
61 (17.9%, 14.0-22.4%) 
45 (13.2%, 9.8-17.3%) 
 
235 (68.9%, 63.7-73.8%) 
 
60 (17.9%, 13.9-22.4%) 
43 (12.8%, 9.4-16.8%) 
 
233 (69.4%, 73.5-82.6%) 
 
<0.001* 
CXR findings (n=403 / 361)      
% Abnormal parenchyma 
(median(IQR), [Range]) 
2.9 (0.4 – 9.2) 
[0 – 51.7] 
 2.1 (0 – 7.1) 
[0 – 70.8] 
<0.001* 
Ring and tramline severity score (0-18) 
(median(IQR), [Range]) 
1 (0 – 3) 
[0 – 13.5] 
 1 (0 – 2.5) 
[0 – 14.5] 
0.100 
* Statistically significant difference between baseline and 12-month values, at p<0.05 level. 
† Symptom questions derived from SGRQ:  Over the past 3-months I have (had shortness of breath / coughed / brought up sputum / 
had attacks of wheezing): not at all / only with chest infections / a few days a month / several days a week / most days a week;  If you 
have tried to work in the past 3-months: my chest trouble does not affect my work / my chest trouble interferes with my work or made 
me change my work / my chest trouble made me stop work; Which of these statements best describes how your chest affects you: It 
does not stop me doing anything I would like to do / It stops me doing 1-2 things I would like to do / it stops me doing most of the 
things I would like to do / It stops me doing everything I would like to do. 
‡ BOLD standard data available for n=365/405 at baseline, n=341/376 at 6-months, and n=336/368 at 12-month study visits. Data age 
/ sex / height standardised using GLI 2012 African American reference ranges to generate z-scores.  
§ Pairwise comparisons between baseline and 12-month data using McNemar’s test for categorical variables, and Student’s t-test / 
Wilcoxon rank sum for continuous variables.  
 
 
Change in respiratory health over one-year 
On average, recovery was seen in respiratory health in the year after treatment completion: the 
prevalence of monthly symptoms declined (60.7% [246/405] to 30.7% [113/368], p<0.001), and 
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average spirometry volumes increased (mean z-score change: FEV1 +0.20 [95% CI: 0.14 – 0.27] and 
FVC +0.33 [95% CI: 0.26 – 0.39]). However, by one-year 12.2% (45/368, 95% CI: 9.1 – 16.0%) still had 
chest symptoms interfering with work, and mean spirometry z-scores remained negative (FEV1 -0.88 
[SD:1.19] and FVC -0.61 [SD:1.09]) (Table 2). In addition, 43.2% (159/368, 95% CI: 38.1 – 48.4%) of 
individuals had experienced a clinically significant deterioration in ≥1 respiratory parameter 
(symptoms, spirometry, or imaging), including 19.3% (59/305, 95% CI: 15.1 – 24.2%) and 14.1% 
(43/305, 95% CI: 10.4 – 18.5%) of participants with a decline in FEV1 and FVC ≥100ml (Table 3).  
Table 3: Proportion of participants experiencing clinically relevant improvement, deterioration or no change in respiratory parameters 
between baseline and one-year study visits, amongst those completing both visits (n=368). Median size of change shown for 
continuous variables. 
Parameter Classification of change 
Proportion of participants with each pattern of change (n, %)* 
Median (IQR) change observed  
Improvement No change Deterioration 
Self-reported general 
health  
Change of ≥1 category 
in self-reported general 
health (poor, fair, good, 
excellent) 
115 (31.3%) 229 (62.2%) 24 (6.5%) 
BMI (kg/m2) Change ≥1.46kg/m2  † 105 (28.5%) 2.7 (1.9 – 4.1) 
244 (66.3%) 
0.2 kg/m2 (-0.2 – 0.8) 
19 (5.2%) 
-2.4 kg/m2 (-3.4 - -1.7) 
SGRQ total score (n=366) Change ≥4units ‡ 
167 (45.6%) 
-16.1 points (-23.8 - -
9.2) 
153 (41.8%) 
-0.4 points (-1.8 – 0) 
46 (12.6%) 
+11.5 points (7.0 – 
25.9) 
6-minute walking distance 
(m) (n=348) Change ≥26m 
‡ 201 (57.8%) 70m (46 – 105m) 
102 (29.3%) 
8m (-4 – 15m) 
45 (12.9%) 
-49m (-65 - -38) 
Presence of monthly 
respiratory symptoms  
Change between 
present / absent 
monthly symptoms 
133 (36.1%) 207 (56.3%) 28 (7.6%) 
FEV1 volume (L) (n=305) Change ≥100ml ‡ 133 (43.6%) 230m (150 – 340) 
113 (37.1%) 
0ml (-40 – 40) 
59 (19.3%) 
-200ml (-230 - -130) 
FVC volume (L) (n=305) Change ≥100ml ‡ 164 (53.8%) 280ml (190 – 400) 
98 (32.1%) 
30ml (-40 – 60) 
43 (14.1%) 
-160ml (-220 - -120) 
% Abnormal parenchyma 
on CXR (n=359) Change ≥4.68% 
† 58 (16.2%) -8.3% (-12.1 - -6.3) 
283 (78.8%) 
0 % (-1.7 – 0.4) 
18 (5.0%) 
+7.9 % (6.3 – 13.3) 
Ring and tramline score 
(0-18) on CXR (n=359) Change ≥1.17 points 
† 79 (22.0%) -2.5 points (-4.0 –2.0) 
218 (60.7%) 
0 points (-0.5 – 0) 
62 (17.3%) 
2.0 points (1.5 – 3.0) 
*Pattern of change over 1-year period, classified using ‘Minimally important clinical difference (MCID)’ cut-offs for continuous 
variables, and change in response category for ordinal variables. Improvement: Increase ≥MCID or improvement by ≥1 category; No 
change: remaining within +/-MCID of baseline reading, or remaining in same category; Deterioration: Reduction ≥MCID or deterioration 
by ≥1 category. 
† No existing MCID agreed in literature: cut-off calculated by 0.5 x standard deviation of baseline data. 
‡ MCID derived from COPD literature(22). 
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Mixed-effects models adjusted for spirometry at TB treatment completion found FEV1 and FVC 
improved by an average of 70ml (95% CI: 45 – 96ml) and 131ml (95% CI: 101 – 161ml) respectively 
over one-year, with the greatest change seen in the first six-months (Table 4). However, recovery was 
incomplete and the strongest predictor of spirometry at any time point was spirometry at TB 
treatment completion (accounting for >90% of total model variance). Accelerated FEV1 or FVC decline 
≥100ml was seen in participants across a wide range of baseline FEV1 and FVC measures (Appendix 
9). The lowest spirometry volumes at one-year were seen in those with the most extensive 
parenchymal pathology or bronchiectasis on HRCT, or the presence of symptoms at TB treatment 
completion. 
Table 4: Multi-level linear regression, to investigate parameters predicting spirometry values in the first year after TB treatment 
completion† (n=347).‡ 
Variable measured at TB 
treatment completion Univariate (ml, 95% CI) 
Multivariate, partial model 
(ml, 95% CI) 
Multivariate, full model (ml, 
95% CI) 
Absolute FEV1 (ml) over follow-up period 
Time from TB treatment end § 
6-months 
12-months 
 
66.70 (47.39 – 86.01)* 
72.73 (48.26 – 97.19)* 
 
62.17 (41.78 – 82.56)* 
65.57 (39.47 – 91.68)* 
 
65.30 (45.00 – 85.61)* 
70.56 (44.58 – 96.54)* 
HIV positive status 197.57 (83.03 – 312.11)* 193.75 (79.43 – 308.08)* 98.61 (-2.01 – 199.22) 
Microbiologically proven TB -61.81 (-194.79 – 71.17) -9.12 (-140.23 – 121.99) 30.82 (-84.35 – 145.98) 
BMI (kg/m2) 18.32 (9.26 – 27.38)* 7.39 (-1.96 – 16.74) 2.20 (-7.01 – 11.40) 
Pack-year smoking history -7.90 (-20.00 – 4.20) -4.90 (-16.79 – 7.00) -0.75 (-11.15 – 9.65) 
Maximum education ≤ 1ry 
school -108.59 (-225.94 – 8.76) -108.26 (-224.69 – 8.18) -37.49 (-139.97 – 64.99) 
Respiratory symptoms ≥monthly -198.98 (-310.07 - -87.90)*  -111.26 (-208.10 - -14.43)* 
Bronchiectasis severity score (0-
18) – 3-point increments ǁ -221.04 (-270.18 - -171.91)  -95.56 (-155.64 - -35.47)* 
Abnormal parenchyma (%) – 
10% increments ** -152.87 (-180.38 - -125.36)  -106.40 (-141.38 - -71.4)* 
Variance components (% of 
model variance): change over 
time  
 1.85% 2.53% 
Variance components (% of 
model variance): baseline FEV1  94.22% 92.05% 
Absolute FVC (ml) over follow-up period 
Time from TB treatment end § 
- 6-months 
- 12-months 
 
124.49 (100.70 – 148.30)* 
145.63 (117.66 – 173.59)* 
 
111.77 (87.04 – 136.50)* 
125.21 (95.26 – 155.16)* 
 
115.38 (90.72 – 140.05)* 
131.28 (101.41 – 161.15)* 
HIV positive status 197.30 (75.42 – 319.18)* 184.22 (64.02 – 304.43)* 92.94 (-18.17 – 204.04) 
Microbiologically proven TB -18.24 (-159.57 – 123.09) 30.45 (-107.28 – 168.17) 65.99 (-61.11 – 193.09) 
BMI (kg/m2) 40.58 (29.97 – 51.19)* 21.34 (10.73 – 31.94)* 15.35 (4.75 – 25.95)* 
Pack-year smoking history -6.04 (-18.88 – 6.81) -4.38 (-16.86 – 8.10) -1.87 (-13.34 – 9.59) 
Maximum education ≤ 1ry 
school -1.34 (-126.72 – 124.04) -2.97 (-125.46 – 199.51) 63.45 (-49.78 – 176.68) 
Respiratory symptoms ≥monthly -200.30 (-318.52 - -82.08)*  -123.61 (-230.53 - -16.69)* 
Bronchiectasis severity score (0-
18) – 3-point increments ǁ -217.87 (-271.12 - -164.62)*  -133.62 (-200.01 - -67.23)* 
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Abnormal parenchyma (%) – 
10% increments ** -131.74 (-162.76 - -100.73)*  -67.03 (-105.67 - -28.39)* 
Variance components (% of 
model variance): change over 
time  
 1.60% 2.01% 
Variance components (% of 
model variance): baseline FVC  93.18% 91.26% 
* OR statistically significant at p<0.05 level. 
† Model construction based on apriori selection of risk-factors / confounders, and elimination of co-linear variables. Interactions with 
time evaluated. All univariate & multivariate models coefficients represent the average change in FEV1 or FVC (ml) expected for a 1-
unit change in the predictor, holding all other parameters still, and include adjustment for participant age (years), sex, and height (cm). 
‡ Participants excluded if absent HIV status at TB treatment completion (n=2), no valid baseline spirometry (n=36), no baseline HRCT 
imaging (n=20). Includes participants contributing either 6-month (n=13) or 12-month (n=322) follow-up.  
§ Negative correlation identified between FEV1 and time (partial model: -0.46 (-0.58 - -0.31) / full model: -0.37 (-0.51 - -0.21)) and FVC 
and time (partial model: -0.56 (-0.68 - -0.40)/ full model: -0.44 (-0.59 - -0.26)) in all models. 
ǁ Bronchiectasis severity score (0-18): unweighted sum of 6x lobar bronchiectasis scores ranging from 0 (no bronchiectasis) to 3 (severe 
dilatation >3 times diameter of adjacent vessel), such that increment of 3 points represents one additional lobe with severe airway 
dilatation, or combination of 1-3 lobes with less severe disease.  
** Total % of parenchymal abnormalities across lung, including: parenchymal banding, atelectasis, consolidation, ground glass change, 
emphysema, emphysematoid destruction, cavities / cystic airspaces. Excluding mosaicism which represents airway/vascular rather 
than lung tissue abnormality. 
 
Chronic respiratory symptoms 
30.7% (113/368, 95% CI: 26.0 – 35.7%) reported respiratory symptoms at one-year, with 
breathlessness being most common (Table 2). On average, participants reporting respiratory 
symptoms at pTB treatment completion were significantly more likely to have symptoms one-year 
later compared to those without baseline symptoms (OR 2.42 [95% CI: 1.37 – 4.27] and 2.45 [95% CI: 
1.39 – 4.32] for FEV1 and FVC models). The odds of respiratory symptoms at one-year were lower in 
HIV-positive compared to HIV-negative participants (OR 0.33 – 0.40 [95% CI: 0.18 – 0.98] across CD4 
groups and models) (Appendix 10). 
Acute respiratory events 
Of participants who contributed six- and 12-months of follow-up data, 25.0% (4/16, 95% CI: 7.3 – 
52.4%) and 15.9% (58/364, 95% CI: 12.3 – 20.1%) experienced ≥1 acute respiratory event. The 
majority had one episode (77.4% [48/62]). Of the 70 unscheduled outpatient visits to local health 
centres or hospitals, 55.7% (39/70, 95% CI: 43.3 – 67.6%) were due to increased cough and 34.3% 
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(24/70, 23.3 – 46.6%) were related to increased breathlessness. Antibiotics were prescribed in 80% 
of cases. 
Participants with respiratory symptoms at treatment completion were more likely to report a 
respiratory event during follow-up (OR 2.6 [95% CI: 1.25–5.42]) compared to those without baseline 
symptoms. HIV-positive adults (12.9% [30/232, 95% CI: 8.9 – 17.9%]) had lower odds of a respiratory 
event compared to HIV-negative participants (21.9% [32/146, 95% CI: 15.5 – 29.5%]) in all models 
and at CD4 counts above and below 200 cells/µL (OR 0.33 – 0.43 [95% CI: 0.13–0.90]) (Appendix 11).  
Controlling for baseline lung pathology the presence of more than one respiratory event during 
follow-up was negatively correlated with FEV1 and FVC volumes at one-year. On average, those with 
≥1 acute respiratory event had FEV1 and FVC volumes which were 82ml (95% CI: 17 –147ml) and 
122ml (95% CI: 51-192ml) lower at one-year compared to those without events (Appendix 12).   
TB retreatment and mortality 
The TB symptom screen (≥1 of current cough, fevers, night sweats, weight loss, haemoptysis) was 
positive in 18.9% (71/376, 95% CI: 15.1 – 23.2%) and 10.6% (39/368, 95% CI: 7.6 – 14.2%) at the six- 
and 12-month visits, with current cough as the most common symptom reported (95.8% [68/71, 95% 
CI: 88.1 – 99.1%] and 92.3% [36/39, 79.1 – 98.4%] at six- and 12-months). Sputum was obtained at 
100/110 of these visits, and only 4% (4/100) had MTB on culture. Three non-tuberculous 
mycobacteria (NTM) isolates were cultured but repeat samples were negative. TB-retreatment was 
initiated in 3.7% (15/404) during follow-up: two culture positive, five smear positive, four Xpert 
MTB/RIF positive, three radiological diagnosis, one unknown. 2.7% (11/404) of participants died, of 
whom 45.5% (5/11) had been initiated on TB retreatment and 90.9% (10/11) were HIV-positive. 
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DISCUSSION  
This study used gold-standard measurement approaches to show that amongst a prospectively 
recruited, unselected cohort of pTB-survivors in a low income, high TB and HIV prevalence setting, 
the burden of PTLD is high: after a single episode of successfully treated pTB disease, one third of 
patients have abnormal spirometry, over 40% have bronchiectasis, and almost 10% have lobar 
destruction. This pathology is largely undiagnosed within existing TB management pathways, but is 
meaningful for patient outcomes, with accelerated lung function decline, ongoing respiratory-related 
health seeking, persistent chest symptoms, and symptoms impairing work seen in 12 – 31% of 
patients in the year after treatment completion. Patterns of PTLD were heterogenous, and although 
less severe amongst HIV-positive compared to negative patients, the burden of disease was marked 
in both groups.  
The finding of a high burden of post-TB lung damage is consistent with previous literature which 
suggests 2-4 fold increased odds of airway obstruction and restriction amongst those who have 
previously had pTB disease compared to those who have not,(2-4) and ongoing airway and 
parenchymal imaging abnormalities following treatment success.(5, 6) Together, these data indicate 
a high population burden of respiratory pathology resulting from pTB disease. 
To our knowledge, this is the first study to track change in lung function in an unselected patient 
cohort prospectively from pTB treatment completion. On average, FEV1 and FVC values for the cohort 
improved over time. Recovery was incomplete, but most marked in the first 6-months. This pattern 
of partial recovery is consistent with previous models,(23) and is in keeping with the parenchymal 
destruction and airway dilatation seen on HRCT imaging which are unlikely to fully resolve.(24, 25) 
However, heterogeneity of lung function outcomes was observed between individuals within the 
cohort: whilst most experienced recovery, up to a fifth had a clinically meaningful decline in lung 
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function over time. These patients are of particular concern given the known associations between 
reduced FEV1 and FVC, and increased mortality.(26-28) In keeping with data from other chronic lung 
diseases, our analyses suggest that acute respiratory events in the year following treatment 
completion may drive worsening spirometry.(12, 13)  
Our data show that PTLD is relevant to patients’ lives and livelihoods. Chest symptoms interfering 
with work were reported by 46% at pTB treatment completion and 12% one-year later. The high costs 
incurred by TB patients during diagnosis and disease treatment are well recognised and have been 
associated with adverse treatment outcomes.(29, 30) However, our findings suggest that post-TB 
morbidity may cause ongoing income losses even beyond treatment completion. These ongoing costs 
are not routinely included in calculations of the economic impact of TB disease, nor is the need to 
address them yet prioritised within the WHO ‘End-TB’ agenda, which aims to mitigate TB-related 
patient costs.(31) 
Almost one third of patients reported ongoing respiratory symptoms at 1-year. Chronic cough is 
stigmatising in high TB and HIV burden settings,(32) and in this study also led to the WHO TB-
symptom screening tool remaining positive for many patients, some months after their initial disease 
episode. Although pTB-survivors are at high risk of recurrent TB disease,(33) empirical TB retreatment 
of pTB-survivors based on chronic symptoms is also widespread.(34) In this study the majority of 
those reporting chronic cough during follow-up did not have microbiological evidence of pTB when 
retested, were not started on TB retreatment, and did not die, highlighting challenges with TB-
screening in the post-TB population.  
HIV-positive adults had less extensive PTLD compared to HIV-negative adults. This difference was 
observed despite little difference in self-reported illness duration prior to TB treatment initiation. The 
HIV-positive patients included in this study had profound immunosuppression with a median CD4 
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count of 229 cells/µL at TB treatment completion. HIV-TB coinfected adults with low CD4 counts have 
been shown to have less extensive CXR changes at TB diagnosis, due to impaired localised cellular 
immune responses to mycobacterial infection, and our data suggest that this translates into less 
extensive residual pathology at TB treatment completion.(35, 36)  However, it is of note that although 
the burden of disease was lower amongst HIV-positive compared to HIV-negative adults, still 
moderate to severe bronchiectasis or abnormal spirometry was seen in a third of this group at pTB 
treatment completion. Most HIV-infected participants in this cohort were initiated on ART close to 
pTB treatment onset, and immune reconstitution on ART has been associated with lung inflammation 
and destruction during early treatment.(37, 38) Findings in this study may reflect a balance between 
the protective effect of low CD4 counts at TB diagnosis on lung tissue, and pro-inflammatory immune 
reconstitution with early initiation of ART. 
Lastly, the heterogeneity of patterns of PTLD in this study was marked. Novel HRCT imaging findings 
included a high burden of mosaicism – this may reflect small airways disease but may also relate to 
pulmonary hypertension, and echocardiography in this cohort would be of value.(39) The high 
prevalence of consolidation, ground-glass and nodules even after six-months of TB treatment was 
striking, but consistent with PET-CT studies from South Africa which show ongoing metabolic activity 
in focal lung lesions of pTB-survivors, due either to persistent mycobacterial disease or a protracted 
host immune response to sterilised infection.(40) The long-term relevance of this residual 
inflammation is not yet clear.  
This is one of the first studies to prospectively investigate the nature and outcomes of post-TB lung 
damage, from the point of TB treatment completion, in a resource poor setting in sSA. The broad 
eligibility criteria mean that findings can likely be generalised to a wide spectrum of adults completing 
treatment in similar settings. Multiple respiratory parameters were measured to comprehensively 
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describe pathology, with high standards of quality control and best-practice reporting, and outcome 
data were collected prospectively. The availability of CT imaging is limited in LMICs, and its inclusion 
is therefore of particular value. Although the study was completed within an urban setting with a 
highly mobile population, loss to follow up was under 10%.  
As patients were not assessed prior to TB disease and no control group was included for comparison, 
the aetiology of lung pathology cannot be confirmed. The short follow-up duration of one-year means 
that models of patient outcomes may have been underpowered and precluded investigation of risk-
factors for TB retreatment or mortality. Observed changes over time may be related to regression to 
the mean, test-retest variation, or participant learning, but MCID cut-offs were used to allow for this. 
Study recruitment required attendance at a central hospital, and a selection bias away from those 
with severe disease may exist. Although this study was observational, participants likely received 
more medical advice than routinely available, and findings may be biased towards improved 
outcomes. 
In summary, this study has found that PTLD is a common and under-recognised consequence of pTB 
that is disabling for patients and associated with adverse outcomes beyond pTB treatment 
completion. Our data highlight the importance of preventing PTLD: further investigation of host, 
environment, and pathogen determinants of the nature and severity of PTLD, including HIV-specific 
factors, are required to identify upstream modifiable risk factor.(41) Host directed therapies, and 
earlier diagnosis through active case finding and improved diagnostics may reduce lung damage, and 
we suggest that the burden of PTLD should be included as a secondary outcome in studies 
investigating the impact of these approaches.  
Evidence-based guidelines for the management of those with established disease are lacking but 
urgently needed.(11) It is not yet clear which interventions would be clinically and cost-effective at 
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maximising health and preventing ongoing decline after pTB treatment completion, but our data 
suggest that appropriate management of respiratory exacerbations, and improved screening 
pathways for recurrent pTB disease should be prioritised. Other low-cost strategies including 
pulmonary rehabilitation and airway clearance exercises require evaluation, and health systems 
capable of providing long-term care to pTB-survivors will be needed to deliver these services.(42) 
Ultimately, we suggest that renewed efforts by the global TB research and practice community to 
address the sequelae of TB disease, beyond treatment completion, will be required to improve long-
term patient well-being.   
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